文献速递前列腺癌

转移性前列腺癌血浆脂质组学揭示肿瘤代谢重编程及雄激素受体靶向治疗的调节作用

Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-03-13

本研究对50例转移性去势抵抗性前列腺癌(mCRPC)患者和14例无癌对照进行血浆定量脂质组学分析,mCRPC患者纵向采样于雄激素剥夺治疗进展后、恩扎卢胺治疗开始后及进展前。结果显示mCRPC患者血浆脂质特征与对照不同,恩扎卢胺显著降低总脂质及特定磷脂和神经酰胺,且治疗后特定鞘脂种类变化与生存相关。

要点

  • mCRPC患者血浆脂质组呈现单不饱和脂质升高及磷脂、鞘脂组成改变。
  • 恩扎卢胺治疗降低总脂质、主要磷脂类和神经酰胺,同时增加鞘磷脂。
  • 恩扎卢胺治疗后特定鞘脂种类定量差异与生存结局相关。

核心结论

  • 血浆脂质组学反映前列腺癌关键代谢特征,受雄激素受体抑制深刻影响,在mCRPC中具有预后相关性。

研究设计与样本

  • 对50例mCRPC患者和14例无癌对照进行血浆定量脂质组学分析,mCRPC患者纵向采样于ADT进展后、恩扎卢胺治疗开始后及恩扎卢胺进展前。

主要发现

  • 与无癌对照相比,mCRPC患者显示独特脂质组特征,单不饱和脂质水平升高,磷脂和鞘脂池组成改变。
  • 恩扎卢胺治疗显著降低总脂质水平,减少主要磷脂类和神经酰胺,同时增加鞘磷脂。
  • 恩扎卢胺治疗后特定鞘脂种类的定量差异与生存结局相关。

临床怎么用

  • 血浆脂质组学有潜力作为无创工具监测mCRPC疾病活动度和治疗反应。
  • 特定鞘脂种类变化可能作为mCRPC预后标志物,并为代谢靶向研究提供线索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reprogrammed lipid metabolism with massive upregulation of tumor cell-autonomous synthesis of saturated fatty acids is a hallmark of prostate cancer (PCa) and is driven in part by aberrations in androgen receptor (AR) signaling. While lipid alterations are well described in primary PCa, the extent to which the circulating lipidome reflects tumor-associated metabolic changes in metastatic disease, and its role in therapy response, remains to be determined. This study aims to assess whether plasma lipid profiling captures tumor metabolic rewiring, and whether this reflects response to AR-targeting therapy, in metastatic castration-resistant PCa (mCRPC). METHODS: Quantitative plasma lipidomics was performed on plasma samples collected from patients with mCRPC (n = 50) and cancer-free subjects (C-FS, n = 14). Samples from patients with mCRPC were collected longitudinally at the time of progression on androgen deprivation therapy prior to initiation of first-line enzalutamide (Enza), after the start of treatment with Enza, before progression on Enza. RESULTS: Compared to C-FS, patients with mCRPC showed distinct lipidomic signatures, characterized by increased levels of monounsaturated lipids and altered composition of the phospholipid and sphingolipid pool, mimicking the aberrations known to occur in primary PCa tissue. Enza treatment markedly reduced total lipid levels, decreased major phospholipid classes and ceramides, while increasing sphingomyelins. Notably, quantitative differences in specific sphingolipid species occurring after Enza treatment correlated with survival outcomes. CONCLUSIONS: Plasma lipidomics reflects key metabolic features of PCa and is profoundly impacted by AR inhibition, with prognostic relevance in patients with mCRPC. These findings support its potential as a non-invasive tool for monitoring disease activity and treatment response, and lay the groundwork for lipid-based biomarkers in mCRPC, while indicating that the lipidomic alterations observed may help inform ongoing and forthcoming research on metabolic targeting.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bleve S, Ravera F, Rodrigues S, et al. Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy. Prostate Cancer Prostatic Dis. 2026. PMID: 41820670. doi:10.1038/s41391-026-01100-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。